Issam Raad, MD
Infectious Disease · Houston, TXNPI 1033215439
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,975 of the $3,076 with a category attached, or 96.7%. Merck accounts for 96.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $2,975 and has fallen 97.7% since, to $69 in 2022.
Across 4 payments — averaging $769.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Melinta Therapeutics, LLC$39
- Astellas Pharma US Inc$32
- La Jolla Pharmaceutical Company$30
Across 25 payments — averaging $79,194 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2M
- Scynexis, Inc.$12K
What the payments were for
- Speaking & faculty fees$2,97597%
- Food & beverage$1013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $2,975 |
| Melinta Therapeutics, LLC | 1 | $39 |
| Astellas Pharma US Inc | 1 | $32 |
| La Jolla Pharmaceutical Company | 1 | $30 |
How this compares
$3,076 in reported general payments places this provider in the 75th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Houston
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- Karen VigilHouston$91K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.